In CRC, KRAS mutations confer resistance to EGFR inhibitors, but KRAS G12C blockade combined with EGFR targeting has proven effective (Fakih et al., 2023; Yaeger et al., 2024). This evidence concerns the gene KRAS and colorectal carcinoma.